Who are HRS-4357 injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): anti-VEGF agent, DMX-200, HR17031 injection, Anti-VEGF Therapy, verteporfin, bevacizumab, triamcinolone acetonide, AG-013736.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hrs-4357-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

HRS-4357 injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HRS-4357 injection (HRS-4357 injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-angiogenic agent / VEGF inhibitor. Area: Oncology.

phase 3 Anti-angiogenic agent / VEGF inhibitor VEGF receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HRS-4357 injection (HRS-4357 injection) — Jiangsu HengRui Medicine Co., Ltd.. HRS-4357 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HRS-4357 injection TARGET	HRS-4357 injection	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Anti-angiogenic agent / VEGF inhibitor	VEGF receptor
anti-VEGF agent	anti-VEGF agent	Medical University of Vienna	marketed	Anti-angiogenic agent (VEGF inhibitor)	VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors
DMX-200	DMX-200	Dimerix Bioscience Pty Ltd	phase 3	Dual VEGF/Ang2 inhibitor	VEGF receptor and Ang2 receptor (Tie2)
HR17031 injection	HR17031 injection	Jiangsu HengRui Medicine Co., Ltd.	phase 3	VEGF inhibitor	VEGF receptor
Anti-VEGF Therapy	Anti-VEGF Therapy	Hoffmann-La Roche	phase 3	VEGF inhibitor	VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors
verteporfin, bevacizumab, triamcinolone acetonide	verteporfin, bevacizumab, triamcinolone acetonide	Shahid Beheshti University of Medical Sciences	phase 3	photosensitizer, monoclonal antibody, corticosteroid	VEGF-A, VEGF receptor
AG-013736	AG-013736	University of Wisconsin, Madison	phase 3	Multi-targeted tyrosine kinase inhibitor	VEGFR (VEGF receptor), PDGFR, and other receptor tyrosine kinases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-angiogenic agent / VEGF inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HRS-4357 injection — Competitive Intelligence Brief. https://druglandscape.com/ci/hrs-4357-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing